Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $719 million initial public offering by Patheon N.V. (“Patheon”). The IPO comprised…
Davis Polk advised McKesson Corporation on its creation of a new health care information technology company, which will combine substantially all of Change Healthcare Holdings, Inc.’s…
Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $54.8 million initial public offering by Aeglea BioTherapeutics, Inc. Aeglea’s…
Davis Polk advised the joint book-running managers and representatives of the several underwriters in the $70.5 million initial public offering by Corvus Pharmaceuticals, Inc. of 4,700,000…
Davis Polk advised the joint book-running managers and representatives of the underwriters in the $182.2 million initial public offering by BeiGene, Ltd. of 7,590,000 American Depositary…
Davis Polk advised the active joint book-running managers and representatives of the underwriters in connection with the $108.6 million initial public offering of 6,785,000 shares of common…
Davis Polk is advising Biotie Therapies Corp. in connection with its combination agreement with Acorda Therapeutics, Inc. where Acorda will make a public tender offer in Finland and the…
Davis Polk is advising Affymetrix, Inc. in connection with its sale to Thermo Fisher Scientific Inc. for a total equity value of approximately $1.3 billion. The transaction, which is…
Davis Polk advised Penumbra, Inc. on its SEC-registered initial public offering of 4,600,000 shares of common stock for an aggregate price to the public of approximately $138 million,…
Davis Polk advised the joint book-running managers in connection with the $138 million initial public offering of common stock of Global Blood Therapeutics, Inc. Global Blood’s common stock…